Does Day One Biopharmaceuticals (DAWN) Have the Potential to Rally 193.16% as Wall Street Analysts Expect?

Group 1 - Shares of Day One Biopharmaceuticals, Inc. (DAWN) have increased by 2.2% over the past four weeks, closing at $12.13, with a mean price target of$35.56 indicating a potential upside of 193.2% [1] - The average price target consists of nine estimates ranging from a low of $25 to a high of$43, with a standard deviation of $5.50, suggesting a potential increase of 106.1% to 254.5% from the current price [2] - Analysts show strong agreement on DAWN's ability to report better earnings than previously predicted, which supports the view of potential upside [4][9] Group 2 - The Zacks Consensus Estimate for DAWN has increased by 4.2% due to two upward revisions in earnings estimates over the last 30 days, with no negative revisions [10] - DAWN holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [11] - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for price movement [12]